Related Experiment Video
Updated: Feb 28, 2026

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
Published on: October 4, 2019
Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells
Emma L Wilkinson1, James E Sidaway1, Michael J Cross1
1Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.
Insights
Statins activate ERK5 signaling in heart cells, strengthening tight junctions and reducing permeability. This ERK5 activation may explain statins' protective effects against doxorubicin-induced heart damage.
Area of Science:
- Cardiovascular Biology
- Cell Signaling
- Endothelial Cell Function
Background:
- The MEKK3/MEK5/ERK5 pathway is crucial for cardiovascular development.
- The role of ERK5 in cardiac endothelial cells and its modulation by statins is not fully understood.
Purpose of the Study:
- To investigate the physiological role of ERK5 in cardiac endothelial cells.
- To determine the effects of statin drugs on ERK5 activation and endothelial cell permeability.
Main Methods:
- Utilized human cardiac microvascular endothelial cells (HCMECs).
- Manipulated ERK5 expression via siRNA and gene overexpression.
- Assessed tight junction formation and cell permeability.
- Examined ERK5 activation and localization upon statin treatment.
Main Results:
- ERK5 regulates endothelial tight junction formation and cell permeability.
- Statin treatment activated ERK5, promoting its translocation to the plasma membrane and co-localization with ZO-1.
- Statins reduced endothelial cell permeability by inhibiting HMG-CoA reductase and isoprenoid synthesis.
- Statin pretreatment protected against doxorubicin-induced disruption of tight junctions and increased permeability.
Conclusions:
- ERK5 plays a key role in regulating endothelial tight junction formation and permeability.
- Statin-induced ERK5 activation decreases cardiac endothelial cell permeability.
- This mechanism may contribute to the cardioprotective effects of statins, particularly in mitigating doxorubicin-induced cardiotoxicity.
Abstract:
The MEKK3/MEK5/ERK5 signaling axis is required for cardiovascular development in vivo. We analyzed the physiological role of ERK5 in cardiac endothelial cells and the consequence of activation of this kinase by the statin class of HMG Co-A reductase inhibitor drugs. We utilized human cardiac microvascular endothelial cells (HCMECs) and altered ERK5 expression using siRNA mediated gene silencing or overexpression of constitutively active MEK5 and ERK5 to reveal a role for ERK5 in regulating endothelial tight junction formation and cell permeability. Statin treatment of HCMECs stimulated activation of ERK5 and translocation to the plasma membrane resulting in co-localization with the tight junction protein ZO-1 and a concomitant reduction in endothelial cell permeability. Statin mediated activation of ERK5 was a consequence of reduced isoprenoid synthesis following HMG Co-A reductase inhibition. Statin pretreatment could overcome the effect of doxorubicin in reducing endothelial tight junction formation and prevent increased permeability. Our data provide the first evidence for the role of ERK5 in regulating endothelial tight junction formation and endothelial cell permeability. Statin mediated ERK5 activation and the resulting decrease in cardiac endothelial cell permeability may contribute to the cardioprotective effects of statins in reducing doxorubicin-induced cardiotoxicity.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Tight Junctions
Intracellular Signaling Affects Focal Adhesions
Some...
Adherens Junctions
Adherens Junctions are Dynamic
Cell-matrix's Response to Mechanical Forces
Anchoring junctions mechanically attach a cell to the...
Tension Response at Adherens Junctions
α-Catenin as a Mechanosensory Protein
The α-catenin of adherens junctions is an allosteric protein with three VH (vinculin...

